Protective effects of Naringin in a rat model of spinal cord ischemia–reperfusion injury

Yongsheng Cui*, Wei Zhao, Xinhua Wang, Mingxin Chen, Li Zhang, Zhilei Liu

Department of Orthopaedics II, Ankang City Central Hospital, Ankang, Shanxi 725000, China

*For correspondence: Email: yongshengcui28@hotmail.com; Tel/Fax: 0086-13-084813344

Received: 31 October 2016 Revised accepted: 12 February 2017

Abstract

Purpose: To evaluate the activity of naringin (NAR) in a rat model of spinal cord ischemic injury (SCII).

Methods: Forty female rats were randomized into four groups: saline without occlusion (control; group I), SCII (group II), 50 mg/kg NAR (group III), or 100 mg/kg NAR (group IV) for 7 days prior to SCI insult (pre-treatment). Neurological and locomotor functions, antioxidant activity, edema and inflammatory markers were determined.

Results: Pre-treatment with NAR considerably lowered the incidence of spinal edema, lipid peroxidation products, and inflammatory markers (TNF-α, NF-κp65, IL-1β, and IL-6). It also successfully reverted the antioxidative activity to near-normal levels and improved locomotor function by protecting spinal tissue from oxidative damage and inflammatory insults. NAR administration effectively downregulated the protein expression of TNF-α and NF-κB p65 subunit in spinal tissue, thus confirming its anti-inflammatory activity.

Conclusion: The results suggest that NAR exhibits neuroprotective effects by inhibiting free radical generation and downregulating inflammatory markers in an SCI rat model.

Keywords: Naringin, Spinal cord injury, Locomotor function, Edema, Oxidative stress, Inflammation

INTRODUCTION

Spinal cord ischemic injury (SCII) is a serious condition that occurs after thoracoabdominal aortic aneurysm (TAAA) surgery and results in muscular disability, particularly paraplegia [1]. The incidence of paraplegia is ~10–30 % after thoracic aortic reconstruction. However, this incidence has increased enormously in recent times, making SCII a serious problem globally [2]. Many current treatment strategies such as hypothermia, partial bypass therapies, and pharmaceutical intervention are recommended to reduce the prevalence of SCII [3]. However, the occurrence of SCII remains high, and these treatments (synthetic drugs) and procedures may trigger various adverse events and thus worsen the patient health status. Hence, treating SCII is a major goal for health professionals and researchers to reduce the prevalence of paraplegia while avoiding adverse events [2].

Several pathological factors may contribute to SCII, but the exact mechanism remains unknown [4,5]. Numerous studies have suggested that oxidative stress (an imbalance between antioxidative and pro-oxidative factors) and inflammation are the pivotal events in SCII [3]. Hence, treating with phytoconstituents that exhibit antioxidant and anti-inflammatory properties might alleviate SCII-related effects. Several recent studies also demonstrated that phytoconstituents such as polyphenols (phenolic or flavonoids) could effectively lower spinal...
edema, inflammation, and oxidative stress and improve neuronal activity (motor function) by inhibiting apoptosis [6,7].

Naringin (NAR) is a bioflavanone glycoside that is found in citrus species. Although NAR cannot be absorbed directly, it can be metabolized by intestinal microflora to yield a metabolite called naringenin, which is an absorbable form of NAR that can effectively cross the blood–spinal cord barrier [8]. NAR exerts several therapeutic and pharmacological activities including antioxidative, anti-inflammatory, anti-angiogenic, antidiabetic, anticancer, and antibacterial effects [9,10]. NAR can also act as a neuroprotective agent against Alzheimer’s disease (AD) and Parkinson’s disease (PD). Moreover, NAR exhibits cardioprotective, hepatoprotective, and renoprotective properties [11,12].

Furthermore, numerous pharmaceutical and nutritional companies have focused on NAR because of its antioxidative and anti-inflammatory properties, and have started to manufacture it as a nutritive or dietary supplement [13]. NAR has also exhibited positive effects in organs such as the brain, heart, and kidney in experimental ischemic–reperfusion (IR) models by reducing oxidative stress and inflammation [14-16]. Nevertheless, no experiments have been conducted to investigate the effects of NAR in SCI, specifically regarding oxidative stress and inflammatory markers.

Hence, we speculate that NAR might protect against spinal cord ischemic injury by suppressing oxidative stress and the inflammatory response in an IR animal model without any adverse events.

**EXPERIMENTAL**

**Chemicals and reagents**

NAR, Tween 20, malondialdehyde (MDA), sodium dodecyl sulfate (SDS), Tris buffer, bromophenol blue, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ketamine, phosphate-buffered saline (PBS), and Tris-buffered saline (TBS), were obtained from Sangon Biotechnology (Shanghai, China). Superoxide dismutase (SOD), glutathione contents (GSH), catalase (CAT), myeloperoxidase (MPO), and lipid peroxidation product (MDA) commercial kits were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All other chemicals used in this study were of analytic grade.

**Experimental animals**

Adult female Sprague-Dawley (SD) rats weighing 300 – 320 g were used in all experiments. They were housed in the animal facility maintained at 25 – 28 °C with 12h light/dark cycles and free access to water and standard rat chow. All experimental procedures were approved by the ethics review board of Ankang City Central Hospital (no. ACCH-35630) and were in conformity with the revised guidelines of the US National Institutes of Health (NIH).

**SCI induction**

SCI injury/insult was performed using the Hwang method [17] with a slight modification. All rats were anesthetized by intraperitoneal (i.p.) injection of 40 mg/kg ketamine and maintained at 37 °C with heating pads and an infrared lamp. A polyethylene catheter was inserted into the tail artery to facilitate continuous monitoring of mean arterial pressure (MAP) and to check the heart rate. A Fogarty balloon catheter was inserted into the descending thoracic aorta through the left femoral artery (midline insertion) and then inflated to induce spinal cord ischemia (occlusion). The ischemia was confirmed by a sudden drop in MAP and heart rate. Then, after 30 min of occlusion, reperfusion (restored blood flow) was initiated by deflating the balloon. Finally, the Fogarty balloon catheter was carefully removed from thoracic aorta, and the rats were allowed to recover from anesthesia. For control rats, all the procedures were carried out except aortic occlusion.

**Experimental groups**

Forty healthy female SD rats were randomly chosen and separated into four groups of 10 rats (n = 10/group). Group I rats received only saline without occlusion ( sham-operated control). Group II rats underwent SCIi, whereas Group III and IV rats underwent SCIi and were treated with 50 and 100 mg/kg NAR (dissolved in saline), respectively, via i.p. injection for 7 days before receiving the SCI insult (pre-treatment) and thus served as the treatment groups (Group III, NAR 50 + SCIi; Group IV, NAR 100 + SCIi).

**Evaluating neurological and locomotor function**

Hind limb movement and neurological function were assessed on days 1, 3, 5, and 7 after SCIi using the Basso, Beattie, and Bresnahan (BBB) motor rating scale. Twenty-one levels of the rating scale were used to evaluate BBB. A value of 0 indicated no detectable hind limb movement,
1 – 8 indicated slight movement of the hind limb joints, 9 meant dorsal stepping, 10 – 20 indicated progressively improved walking ability, and 21 meant normal movement without any discomfort.

Assessment of edema

Edema was measured according to the method described by Mdzinarishvili [18] with slight modifications. The dry and wet weights of spinal samples were quantified to calculate edema based on the percentage difference between the two weights (dry/wet weight).

Evaluation of antioxidant activity

SOD, GSH, and CAT activities and lipid peroxidation products (MDA) were evaluated in spinal tissue homogenates using commercial kits according to the experimental protocol.

MPO activity

Neutrophil infiltration was assessed by measuring MPO activity in spinal homogenates using an MPO assay kit according to the manufacturer’s instructions. One unit of MPO activity was defined as the amount of enzyme required to degrade 1 mmol peroxidase/min at 25 °C and is expressed as units per gram (U/g) of wet weight tissue.

Inflammatory markers

To analyze nuclear factor-kappa B (NF-κB) active subunit (NF-κB p65) in spinal homogenates, nuclear fractions were extracted using a nuclear extraction kit (Abcam, Cambridge, UK), and then levels were measured using an NF-κB p65 transcription factor assay kit (Abcam) according to the manufacturer’s instructions. The levels of tumor necrosis factor-α (TNF-α), IL-1β, and IL-6 were measured in spinal tissue cytosolic fractions using commercial ELISA kits (Thermo Fisher Scientific, Waltham, MA, USA) in accordance with the manufacturer’s protocols.

Western blot

The protein content of samples was estimated using BCA assay kits (Beyotime, Biotechnology, Jiangsu, China). Equal protein quantities (40 µg/lane) were loaded into 8 % sodium dodecyl sulfate-polyacrylamide gels and then transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5 % skimmed milk and Tween 20 containing Tris-buffered saline (TBS) and then incubated with primary antibodies overnight at 4 °C. The following primary antibodies were used: rabbit polyclonal anti-NF p65 (1:1200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TNF-α (1:2000; Santa Cruz), mouse anti-rat β-actin (1:500; Zhongshan Biotechnology, Beijing, China), and anti-rabbit-histone H3 (1:1000; Zhongshan Biotechnology; internal control). After TBS was used to remove unbound antibodies, membranes were incubated with anti-goat and anti-mouse secondary antibodies conjugated to horseradish peroxidase (HRP) (1:1000 and 1:2000, respectively; Santa Cruz Biotechnology) in TBS at room temperature for 1 h. After washing again with TBS, the absorbance was assessed using an enhanced chemiluminescent system (Thermo Fisher Scientific, Waltham, MA, USA), and the signals were quantified using ImageJ software (NIH, Bethesda, MD, USA).

Statistical analysis

Data are expressed as mean ± standard deviations (SDs). Significance differences between the control group and treatment groups were assessed using one-way analysis of variance (ANOVA) with Statistical Package for the Social Science (SPSS) software (IBM, New York, NY, USA). The least significant difference (LSD) was determined using post hoc multiple-comparison tests. *P* < 0.05 was considered to indicate statistical significance.

RESULTS

Effect of NAR on locomotor function

Table 1 shows the locomotor function (hind limb movement or neurological function) of experimental rats. Sham-operated control rats exhibited normal hind limb movement on days 3, 5, and 7. SCII rats exhibited significantly reduced (p < 0.01) hind limb movement, as evidenced by paraplegia and the lowest BBB score on days 1, 3, 5, and 7. However, treatment with NAR (50 and 100 mg/kg) significantly improved (p < 0.05) the locomotor function by abolishing neuronal damage, as indicated by an improved BBB score compared with SCII rats.

Effect of NAR on spinal edema

The effects of NAR on spinal edema in experimental rats are illustrated in Fig. 1A. Although no edematous changes were observed in sham-operated rats, a considerable increase in the levels of spinal edema was seen in SCII rats (*P* < 0.01). NAR administration (500 and 100 mg/kg) significantly suppressed edema compared with SCII rats (*P* < 0.05).
Table 1: Effect of NAR on spinal function (BBB score) in experimental rats

<table>
<thead>
<tr>
<th>Group</th>
<th>1st day</th>
<th>3rd day</th>
<th>5th day</th>
<th>7th day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>19.00 ± 2.00</td>
<td>20.50 ± 1.50</td>
<td>21.00 ± 2.00</td>
<td>21.00 ± 2.00</td>
</tr>
<tr>
<td>SCII</td>
<td>4.01 ± 0.3 a a</td>
<td>8.86 ± 0.73 a a</td>
<td>11.85 ± 1.25 a a</td>
<td>14.07 ± 1.60 a a</td>
</tr>
<tr>
<td>NAR 50 + SCII</td>
<td>8.67 ± 0.62 b b*</td>
<td>13.81 ± 1.20 b b*</td>
<td>15.32 ± 0.92 b b*</td>
<td>16.64 ± 1.80 b b*</td>
</tr>
<tr>
<td>NAR 100 + SCII</td>
<td>9.44 ± 0.91 b b*</td>
<td>14.56 ± 1.68 b b*</td>
<td>16.76 ± 0.78 b b*</td>
<td>18.95 ± 2.08 b b*</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SDs of 10 rats in each group; *p < 0.05, #p < 0.01 SCII group vs. sham control group (a) and treatment groups (NAR 50, 100) vs. SCII group (b).

Effect of NAR on MPO activity

The effects of NAR on spinal MPO activity (neutrophil infiltration) in the experimental rats are shown in Fig. 1B. Spinal MPO activity was increased significantly (P < 0.01) in the SCII group compared with the sham-operated control group. Pre-treatment with NAR (50 and 100 mg/kg) for 7 days significantly reduced MPO activity (P < 0.01) via its anti-inflammatory effects.

Effect of NAR on antioxidant activity

The effects of NAR on the activity of endogenous antioxidant products in experimental rats are shown in Table 2. The activity of SOD, GSH, and CAT was significantly reduced in SCII rats compared with sham-operated control rats (p < 0.05). Treatment with both 50 mg/kg and 100 mg/kg NAR significantly increased the activity of SOD, GSH, and CAT (p < 0.05 and p < 0.01, respectively) compared with SCII rats by alleviating oxidative stress. Although the levels of lipid peroxidation products such as MDA were increased in the SCII group, treatment with NAR significantly lowered lipid peroxidation products (50 mg/kg, p < 0.01; and 100 mg/kg, p < 0.01), confirming its antioxidant activity.
Table 2: Effects of NAR on spinal lipid peroxidation and antioxidant activity in experimental rats

<table>
<thead>
<tr>
<th>Group</th>
<th>MDA (nmol/mg protein)</th>
<th>SOD (U/mg protein)</th>
<th>CAT (U/mg protein)</th>
<th>GSH (µg/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.82 ± 0.09</td>
<td>3.45 ± 0.32</td>
<td>66.60 ± 7.53</td>
<td>9.34 ± 1.10</td>
</tr>
<tr>
<td>SCII</td>
<td>1.65 ± 0.12 a</td>
<td>2.08 ± 0.21 a</td>
<td>48.04 ± 4.09 a</td>
<td>6.24 ± 0.81 a</td>
</tr>
<tr>
<td>NAR 50 + SCII</td>
<td>1.18 ± 0.08 b</td>
<td>2.99 ± 0.38 b</td>
<td>55.83 ± 6.22 b</td>
<td>7.84 ± 0.77 b</td>
</tr>
<tr>
<td>NAR 100 + SCII</td>
<td>0.92 ± 0.11 b</td>
<td>3.24 ± 0.46 b</td>
<td>61.72 ± 9.14 b</td>
<td>9.06 ± 1.12 b</td>
</tr>
</tbody>
</table>

Data are expressed as the means ± SDs of 10 rats per group. *p < 0.05; **p < 0.01; SCII group vs. control group (a) and treatment groups (NAR 50, 100 mg/kg) vs. SCII group (b). One unit (U) of SOD inhibits the rate of increase in absorbance at 550 nm by 50% under assay condition. One unit (U) of CAT activity was defined as 1 mg of tissue proteins that consumed 1 µmol H₂O₂ at 405 nm in 1 s.

Table 3: Effect of NAR on the activity of inflammatory markers in the spinal tissues of experimental rats

<table>
<thead>
<tr>
<th>Group</th>
<th>TNF-α (pg/mg protein)</th>
<th>NF-κB p65 (pg/mg protein)</th>
<th>IL-1β (ng/mg protein)</th>
<th>IL-6 (pg/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>135.72 ± 14.50</td>
<td>68.56 ± 7.13</td>
<td>73.06 ± 8.22</td>
<td>101.34 ± 11.41</td>
</tr>
<tr>
<td>SCII</td>
<td>310.02 ± 26.77 a</td>
<td>185.45 ± 18.48 a</td>
<td>194.50 ± 17.25 a</td>
<td>215.48 ± 26.11 a</td>
</tr>
<tr>
<td>NAR 50 + SCII</td>
<td>211.40 ± 23.05 b</td>
<td>122.82 ± 13.03 b</td>
<td>128.14 ± 10.93 b</td>
<td>157.11 ± 15.09 b</td>
</tr>
<tr>
<td>NAR 100 + SCII</td>
<td>154.83 ± 16.49 b</td>
<td>81.08 ± 9.62 b</td>
<td>90.13 ± 11.01 b</td>
<td>120.11 ± 13.68 b</td>
</tr>
</tbody>
</table>

Data are expressed as the means ± SD of 10 rats per group. *p < 0.05, p < 0.01; SCII group vs. control group (a) and treatment groups (NAR 50, 100 mg/kg) vs. SCII group (b).

Effects of NAR on inflammatory markers

The effects of NAR on inflammatory markers including TNF-α, NF-κB p65, IL-1β, and IL-6 in experimental rats are presented in Table 3. A significant increase in the levels of TNF-α, NF-κB p65, IL-1β, and IL-6 was observed in the spinal tissue of SCI rats compared with sham-operated rats (p < 0.01). NAR administration significantly lowered the levels of TNF-α, NF-κB p65, IL-1β, and IL-6, suggesting anti-inflammatory properties.

Effects of NAR on protein expression

Western blotting was employed to quantify the protein expression of inflammatory markers including TNF-α and NF-κB p65 in the spinal tissues of experimental rats Fig. 2. The expression of TNF-α (cytosolic fraction) and NF-κB p65 (nuclear fraction) was significantly upregulated in the SCII group compared with the sham-operated control group (P < 0.01). Seven-day pretreatment with NAR significantly downregulated the protein expression of TNF-α and NF-κB p65.

DISCUSSION

The current study demonstrated that pretreatment with NAR for 7 days prior to SCII prevented neurological deficits and neuronal loss, and improved locomotor function. In addition, treatment with NAR substantially alleviated various pathological conditions such as edema, neutrophil infiltration (MPO), oxidative stress, and inflammation. NAR also downregulated the levels of major nuclear transcription factors (NF-κB p65) and pro-inflammatory cytokines (TNF-α) to suppress the activation of glia and neutrophils (which produce excessive free radicals) and the subsequent inflammatory cascade. To the best of our knowledge, this is the first experimental study to demonstrate the neuroprotective effects of NAR against SCII.

The BBB screening scale is used to assess the neuroprotective efficacy of any drugs that are linked to hind limb movement [17]. The BBB score was significantly decreased in SCII rats because of oxidative stress (excessive free radical generation), which damages the myelin sheath of neurons, eventually leading to neuronal apoptosis or death. These results are consistent with a report by Fan et al [19]. Furthermore, NAR-treated rats had a significantly decreased BBB score, which was caused by NAR’s free radical scavenging activity. Similarly, NAR supplementation after carotid artery occlusion (ischemia) substantially increased locomotor activity [14].

Spinal edema or water content was analyzed to check the integrity of the neurological system. During the induction of SCII, several vasoactive substances are synthesized that initiate the breakdown of the blood spinal cord barrier and increase blood pressure, leading to increased water content (edema) in the spinal cord [3].
Consistent with this, rats that underwent ischemia–reperfusion injury exhibited increased edema compared with the sham control group in the current study. However, treatment with NAR significantly lowered the levels of edema via its vasoprotective and neuroprotective activity. These results are consistent with the findings of Rong et al [8], who also indicated that NAR could reduce edema in a rat model.

The spinal tissue is extremely vulnerable to oxidative stress because it has a high oxygen utilization rate, high polyunsaturated fatty acids content, low levels of antioxidants, and high water content [20]. Several studies also suggested that ischemic–reperfusion injury reduced the activity of endogenous antioxidants, due to excessive free radical production (hypoxia), and subsequent oxidative stress [21,22]. Similarly, the activity of various endogenous antioxidant systems including SOD, GSH, and CAT was decreased, whereas MDA levels were increased due to the overproduction of free radicals (ROS/RNS) in the current study. Treatment with 50 and 100 mg/kg NAR improved antioxidant activity and reduced lipid peroxidation product formation. This suggests that NAR possesses potent free radical quenching ability and triggers endogenous antioxidant production. Moreover, previous studies revealed that NAR can activate nuclear factor-erythroid related factor-2, which is responsible for the synthesis of antioxidants, particularly SOD, CAT, and glutathione [10,23].

Oxidative stress and inflammation play crucial roles in the pathogenesis of SCII. These two processes are interconnected (vicious cycle) and are thus implicated in most chronic diseases. After SCII insult, leukocytes (especially neutrophils and macrophages) begin to accumulate near the ischemic region and then slowly infiltrate into the spinal cord. They then activate microglial cells and other endothelial cells to stimulate the production of excessive amounts of inflammatory factors, including pro-inflammatory cytokines and free radicals [24]. The activated glial cells and neutrophils produce more inflammatory mediators, worsening the ischemic injury. Thus, leukocyte (neutrophil) infiltration initiates SCII. Accordingly, in the current study, the rate of neutrophil infiltration was assessed by measuring the activity of MPO in SCII tissues. Spinal MPO activity was increased in the SCII group. However, treatment with NAR (50 and 100 mg/kg) significantly reduced MPO activity via its anti-inflammatory activity. Golechha et al [25] demonstrated that different doses of NAR significantly lowered the
levels of inflammatory mediators in a rat model via anti-inflammatory effects.

During SCI, activated glial cells and neutrophils might trigger an inflammatory cascade by upregulating NF-κB and its downstream genes, especially proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. Therefore, the concentrations of inflammatory markers in spinal tissue were examined in the current study. Significant increases in the concentrations of TNF-α, NF-κB p65, IL-1β, and IL-6 were observed in the SCII group. However, NAR significantly reduced inflammatory marker concentrations to near-normal levels, thus confirming its anti-inflammatory activity. These data are consistent with the observations by Chen et al [26], who demonstrated that NAR could lower the levels of lower inflammatory markers.

NF-κB is a nuclear transcriptional factor that is highly expressed in infected tissues or cells. It modulates the expression of many inflammatory markers and proinflammatory cytokines and thereby regulates the inflammatory cascade [26]. The abovementioned biochemical analyses revealed that NAR attenuates the concentration of various inflammatory markers; to confirm these results, the protein expression of TNF-α and NF-κB p65 were quantified. Previous studies have revealed that the activation of NF-κB p65 is a crucial event during the induction of SCII in several animal models [3,27]. As indicated above, the protein expression of both NF-κB (cytosolic fraction) and NF-κB p65 (nuclear fraction) was significantly upregulated during SCII due to excessive oxidative stress and inflammation. Pretreatment with NAR significantly downregulated the protein expression of TNF-α and NF-κB p65, indicating its antioxidant and anti-inflammatory activities. Sahu et al reported that supplementation with NAR significantly downregulated the protein expression of NF-κB and thus decreased pro-inflammatory cytokine production in a rat model [13]. Hence, we propose that NAR directly inhibits the activation of NF-κB, especially in nuclear fractions, and thus suppresses the production of pro-inflammatory cytokines.

CONCLUSION

Pretreatment with 50 and 100 mg/kg NAR afford effective neurotherapeutic activity by increasing antioxidant activity to restrain oxidative stress. NAR supplementation also inhibits excessive inflammatory cytokine production by inhibiting the activation of NF-κB p65 and TNF-α in a rat model of SCII. Thus, NAR enhances locomotor activity and protects spinal tissue from SCII insult-induced damage. Both doses of NAR also stimulate potent neuroprotective activity, although 100 mg/kg of NAR-100 was more potent than the 50 mg/kg dose. Future studies are required to confirm these findings as well as elucidate the mechanism of these neuroprotective effects.

DECLARATIONS

Acknowledgement

Financial aid for this work was received from Ankang City Central Hospital, Ankang, Shanxi 725000, China.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea d), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES


Trop J Pharm Res, March 2017; 16(3): 656